Global Micro-Invasive Glaucoma Implants Market Size By Type (Main Stream, Side Stream), By Application (Hospitals, Homecare), By Region, And Segment Forecasts, 2023 to 2032

The Global Micro-Invasive Glaucoma Implants Market was valued at USD 587.3 million in 2023 and is projected to surpass USD 1.12 billion by 2031, expanding at a CAGR of 8.3% during the forecast period from 2023 to 2031. Micro-invasive glaucoma surgery (MIGS) implants are revolutionizing the treatment of glaucoma by offering a safer and less invasive alternative to traditional surgeries. The increasing prevalence of glaucoma, growing geriatric population, and rising preference for minimally invasive procedures are key factors driving market expansion. Furthermore, advancements in implant technologies and an increasing awareness of early glaucoma diagnosis are fueling demand globally.

Drivers:

Rising Prevalence of Glaucoma:

With over 76 million individuals affected by glaucoma globally, the need for effective long-term treatment solutions is rising. Micro-invasive implants provide an efficient method to reduce intraocular pressure (IOP), making them a preferred option among ophthalmologists.

Advancements in Implant Technology:

Continuous innovations, such as bio-compatible materials, improved delivery systems, and multi-site implantation capabilities, are enhancing the effectiveness and adoption of MIGS devices.

Growing Preference for Minimally Invasive Surgery:

Patients and surgeons are increasingly opting for micro-invasive procedures due to their faster recovery times, reduced complication rates, and minimal disruption to ocular anatomy compared to traditional surgeries like trabeculectomy.

Restraints:

High Cost of Implants and Surgical Procedures:

Despite their clinical benefits, the high costs associated with MIGS devices and associated procedures may limit their adoption in cost-sensitive regions and among uninsured patients.

Limited Reimbursement in Emerging Economies:

In developing markets, insufficient reimbursement policies for novel glaucoma treatments hinder broader accessibility and utilization of MIGS devices.

Opportunity:

Expanding Healthcare Infrastructure in Emerging Markets:

Rising investments in eye care facilities, combined with improving access to ophthalmologists in regions like Asia-Pacific and Latin America, are unlocking new growth avenues.

Integration with Digital Ophthalmology Platforms:

Combining MIGS procedures with diagnostic imaging and AI-powered monitoring tools can improve surgical outcomes and personalized care, presenting opportunities for device manufacturers to innovate further.

Market by System Type Insights:

The market is segmented into Schlemm's Canal Devices, Suprachoroidal Space Devices, and Subconjunctival Devices. In 2023, Schlemm’s Canal Devices accounted for the largest market share, owing to their favorable safety profile and compatibility with cataract surgeries. These devices bypass the trabecular meshwork, facilitating aqueous outflow and reducing IOP effectively. The Suprachoroidal Devices segment is expected to witness the fastest growth, driven by increasing clinical evidence supporting their efficacy and durability.

Market by End-use Insights:

Based on end-use, the market is categorized into Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers. Hospitals dominated the market in 2023, due to the availability of advanced surgical infrastructure and skilled professionals. Ambulatory Surgical Centers are projected to experience the highest CAGR, supported by the increasing demand for outpatient glaucoma surgeries and shorter post-operative recovery.

Market by Regional Insights:

North America led the global micro-invasive glaucoma implants market in 2023, attributed to strong healthcare infrastructure, high glaucoma prevalence, and favorable reimbursement structures. Europe follows closely, driven by rising elderly populations and supportive regulatory frameworks. However, the Asia-Pacific region is expected to register the highest growth rate, propelled by expanding healthcare access, a growing middle class, and increasing awareness about early glaucoma diagnosis and treatment.

Competitive Scenario:

Leading players in the market include Glaukos Corporation, Alcon Inc., Ivantis Inc. (a subsidiary of Alcon), Santen Pharmaceutical Co., Ltd., New World Medical Inc., MicroOptx, iStar Medical, and Allergan (AbbVie Inc.). These companies are focusing on clinical research, regulatory approvals, and strategic collaborations to strengthen their market position.

Key developments include:

In 2023, Glaukos Corporation announced FDA clearance for its iStent infinite®, offering a standalone solution for patients not undergoing cataract surgery.

Alcon Inc. expanded its glaucoma device portfolio through enhanced distribution of Hydrus® Microstent across European markets.

iStar Medical received CE mark approval in 2024 for MINIject®, a suprachoroidal device for open-angle glaucoma, accelerating its commercialization in the EU.

Scope of Work – Global Micro-Invasive Glaucoma Implants Market

Report Metric Details

Market Size (2023) USD 587.3 million

Projected Market Size (2031) USD 1.12 billion

CAGR (2023–2031) 8.3%

Market Segments System Type (Schlemm’s Canal, Suprachoroidal, Subconjunctival), End-use (Hospitals, Clinics, ASCs), Region

Growth Drivers Aging population, glaucoma prevalence, preference for minimally invasive surgery

Opportunities Growth in emerging markets, digital health integration

Key Market Developments:

2023: Glaukos Corporation launched next-gen iStent infinite® in the U.S. for standalone glaucoma therapy.

2024: iStar Medical secured EU market entry for MINIject® after successful trials across multiple centers.

2024: Alcon initiated Phase IV studies to assess long-term outcomes of the Hydrus® Microstent post-cataract surgery.

FAQs:

What is the current market size of the Global Micro-Invasive Glaucoma Implants Market?

The market was valued at USD 587.3 million in 2023.

What is the major growth driver of the Global Micro-Invasive Glaucoma Implants Market?

The primary growth driver is the rising preference for minimally invasive procedures to manage glaucoma effectively.

Which is the largest region during the forecast period in the Global Micro-Invasive Glaucoma Implants Market?

North America held the largest market share in 2023, with Asia-Pacific projected to be the fastest-growing region.

Which segment accounted for the largest market share in Global Micro-Invasive Glaucoma Implants Market?

Schlemm’s Canal Devices led the market by system type in 2023.

Who are the key market players in the Global Micro-Invasive Glaucoma Implants Market?

Glaukos Corporation, Alcon Inc., Ivantis Inc., Santen Pharmaceutical, and New World Medical are key